Navigation Links
New approach to cancer: Find most tightly controlled genes
Date:7/17/2008

DURHAM, N.C., and SINGAPORE Scientists at a Duke University medical school in Singapore have found a new way to study cancer that could be very useful for developing targeted therapies against cancer and possibly many other diseases.

"Because all you need for this approach is gene expression data to compare both diseased and normal tissues, you could apply it to cancer or any other disease, if you have the data," said co-author and researcher Patrick Tan, M.D., Ph.D., associate professor of Duke-NUS Graduate Medical School Singapore. "Just replace the word 'cancer' with 'diabetes,' 'obesity,' and so on."

Surveying large amounts of genetic data, the scientists analyzed both cancerous and healthy, normal tissue for genes with tightly controlled activity.

They defined "tightly controlled" as genes that varied the least during their expression. Gene expression is the process through which a gene is turned on to make certain products, such as proteins.

In cases where the same genes were active in both diseased and normal tissue, they narrowed their search to the genes that are more tightly controlled in cancerous tissue. The diseased and normal samples used came from lung, thyroid, liver, esophagus, colon and breast tissues.

"We thought that since the tumors were spending costly cellular resources and energy to control the expression of these particular genes, they must have functional importance in cancer," said Dr. Tan, who is also a principal investigator with the National Cancer Centre and group leader in the Genome Institute of Singapore.

The work, published in the July 18 issue of PLoS Genetics, was funded by the National Cancer Centre of Singapore and a grant from the Biomedical Research Council of Singapore.

Forty-eight genes that are tightly controlled in tumors emerged from the analysis. The scientists referred to this collection as a "poised gene cassette" or PGC.

"We view the PGC genes as an exciting new class of genes, in which you would only need to slightly affect gene function to elicit a sizeable effect on the tumor," Tan said. "This would make the PGC genes attractive targets."

For example, a treatment targeting a PGC gene might only need to inhibit protein activity by 10-20 percent in order to gain the desired effect. This contrasts with other genes, where a near-complete inhibition (90-100 percent) might be required before effects on tumors are seen.

The scientists studied what happens with some of these genes in the PGC by comparing different samples of tumor tissue that were known to be more or less metastatic (able to spread to other places in the body). They found that the PGC expression was subtly yet significantly lower in highly metastatic cells.

Their analysis also found that the PGC genes were not tightly regulated in several data sets taken from noncancerous tissue. This provided more evidence that the PGC genes are regulated specifically in cancerous tissue. "Our findings suggest that small changes in PGC expression in tumors may be linked with potent differences in a tumor's ability to spread or be invasive," Tan said.

"Beyond cancer, we could easily apply this approach to other diseases," Tan said. "With the right data, researchers could find genes related strictly to disease progression and explore how they can be manipulated to our benefit."


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. New approach sheds light on ways Circadian disruption affects human health
2. Kognitio CEO Offers Outsourced, Service-Based Data Warehousing as a New Approach to Large Scale Analytics
3. First steps towards a new approach to epilepsy treatment
4. Non-Surgical Approach Can Treat Lung Cancers
5. Weizmann Institute scientists develop a new approach to treating autoimmune disease
6. New vaccine approach prevents/reverses diabetes in lab study at Childrens Hospital of Pittsburgh
7. NIAID to advance B-cell approach to HIV vaccines
8. Research Converging in Favor of New Approach to U.S. Weight Problem
9. New approach to protect the hearts of patients with muscular dystrophy
10. Teens think they have asthma under control, but benefit from new approach to treatment
11. Studies test new approaches to islet transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... Scottsdale, AZ (PRWEB) , ... ... ... pioneer, ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus ... , WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg Leyer, the ... Probiotic Association’s Washington DC workshop on November 2nd. The conference was an opportunity ... probiotic dietary supplement regulations. , Dr. Leyer spoke about two main topics ...
(Date:12/6/2016)... ... 2016 , ... The International Vaccine Institute (IVI) and GeneOne ... Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development ... in the event of a future outbreak. , IVI and GeneOne held a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... the ralinepag phase 2 trial.  Ralinepag is an oral, ... the treatment of pulmonary arterial hypertension (PAH). The study ... "This marks an important step in the development of ... our pipeline," said Amit Munshi , Arena,s President ...
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink Inc ... for connecting the Life Sciences supply chain and ... today announced that Tjoapack has selected TraceLink,s serialization ... customers comply with the rapidly approaching serialization deadlines ... (DSCSA) in 2017 and the EU Falsified Medicines ...
(Date:12/7/2016)... ZIONA SCIENCE PARK , ... biotechnology company Kadimastem (TASE: KDST) announced today the signing of a ... collaboration between the companies. The synergy between the companies will assist ... collaboration as a worldwide leader in innovative treatment for severe diseases ... ...
Breaking Medicine Technology: